Laura Sierra has over 10 years of experience in translational and clinical research, holding increasingly responsible roles in clinical development contributing to pivotal programs and successful approval for Tazemetostat in epithelioid sarcoma at Epizyme and the IND opening trial for oral PD-L1 inhibitor at Incyte. She holds a PhD in Integrative and Molecular Biomedical Science for Baylor College of Medicine.